The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Analysis on the current status of targeted drug delivery to tumors
Open accessAbstract
Targeted drug delivery to tumor sites is one of the ultimate goals in drug delivery. Recent progress in nanoparticle engineering has certainly improved drug targeting, but the results are not as good as expected. This is largely due to the fact that nanoparticles, regardless of how advanced they are, find the target as a result of blood circulation, like the conventional drug delivery systems do. Currently, the nanoparticle-based drug delivery to the target tumor tissues is based on wrong assumptions that most of the nanoparticles, either PEGylated or not, reach the target by the enhanced permeation and retention (EPR) effect. Studies have shown that so-called targeting moieties, i.e., antibodies or ligands, on the nanoparticle surface do not really improve delivery to target tumors. Targeted drug delivery to tumor sites is associated with highly complex biological, mechanical, chemical and transport phenomena, of which characteristics vary spatiotemporally. Yet, most of the efforts have been focused on design and surface manipulation of the drug carrying nanoparticles with relatively little attention to other aspects. This article examines the current misunderstandings and the main difficulties in targeted drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Targeted drug delivery to tumors: Myths, reality and possibility
Bae, Y. H., & Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.001 · Cited by 1,935
Self-citationHuman serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., & Jain, R. K. (1994) · PubMed · Cited by 908
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation
Brown, E., McKee, T., diTomaso, E., Pluen, A., Seed, B., Boucher, Y., & Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm879 · Cited by 836
Impact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Folate receptor targeted biodegradable polymeric doxorubicin micelles
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.003 · Cited by 620
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
Lee, E. S., Na, K., & Bae, Y. H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.12.018 · Cited by 577
Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium
Ramanujan, S., Pluen, A., McKee, T. D., Brown, E. B., Boucher, Y., & Jain, R. K. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)73933-7 · Cited by 552
Nanoparticles that communicate in vivo to amplify tumour targeting
Park, J., Lin, K., Singh, N., Schwöppe, C., Mesters, R. M., Berdel, W. E., Ruoslahti, E. I., Sailor, M. J., von Maltzhan, G., & Bhatia, S. N. (2010) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 500
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics
Baxter, L. T., & Jain, R. K. (1990) · Microvascular Research · doi:10.1016/0026-2862(90)90023-k · Cited by 363
(1999) · PubMed · Cited by 348
de Smet, M., Heijman, E., Langereis, S., Hijnen, N. M., & Grüll, H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.036 · Cited by 330
Mikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C. M., Hartung, G., Maier-Borst, W., & Heene, D. L. (1997) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(97)00015-2 · Cited by 305
Ishida, T., Ichihara, M., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.001 · Cited by 270
Nanosystem drug targeting: Facing up to complex realities
Ruenraroengsak, P., Cook, J. M., & Florence, A. T. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.032 · Cited by 265
Grantab, R., Sivananthan, S., & Tannock, I. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3077 · Cited by 254
Nanotechnology: What it can do for drug delivery
Park, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.003 · Cited by 239
Self-citationPaulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Koo, A. N., Min, K. H., Lee, H. J., Lee, S.-U., Kim, K., Chan Kwon, I., Cho, S. H., Jeong, S. Y., & Lee, S. C. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.013 · Cited by 196
Self-citationComparison of five different targeting ligands to enhance accumulation of liposomes into the brain
van Rooy, I., Mastrobattista, E., Storm, G., Hennink, W. E., & Schiffelers, R. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.014 · Cited by 188
Tam, J. M., Tam, J. O., Murthy, A., Ingram, D. R., Ma, L. L., Travis, K., Johnston, K. P., & Sokolov, K. V. (2010) · ACS Nano · doi:10.1021/nn9015746 · Cited by 186
Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors
Alexandrakis, G., Brown, E. B., Tong, R. T., McKee, T. D., Campbell, R. B., Boucher, Y., & Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm981 · Cited by 178
The benefits and challenges associated with the use of drug delivery systems in cancer therapy
Cukierman, E., & Khan, D. R. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.020 · Cited by 162
Davies, C. D. L., Berk, D. A., Pluen, A., & Jain, R. K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600270 · Cited by 121
Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy
Salnikov, A. V., Iversen, V. V., Koisti, M. J., Sundberg, C., Johansson, L. O. M., Stuhr, L. E. B., Sjöquist, M., Ahlström, H. K., Reed, R. K., & Rubin, K. (2003) · The FASEB Journal · doi:10.1096/fj.02-1201fje · Cited by 116
Cirstoiu-Hapca, A., Buchegger, F., Lange, N., Bossy-Nobs, L., Gurny, R., & Delié, F. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.026 · Cited by 105
Lü, W., Xiong, C., Zhang, R., Shi, L., Huang, M. L., Zhang, G., Song, S., Huang, Q., Liu, G.-Y., & Li, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.014 · Cited by 86
Damia, G. L. M., & D’Incalci, M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.08.008 · Cited by 84
To PEGylate or not to PEGylate, that is not the question
Park, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.025 · Cited by 70
Self-citationRubin, K., Sj�quist, M., Gustafsson, Å., Isaksson, B., Salvesen, G. S., & Reed, R. K. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000601)86:5<636::aid-ijc6>3.0.co;2-r · Cited by 60
Albumin: A versatile carrier for drug delivery
Park, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.015 · Cited by 58
Self-citationBansal, R., Post, E., Proost, J. H., de Jager-Krikken, A., Poelstra, K., & Prakash, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.027 · Cited by 55
STRØMHAUG, P. E., Berg, T., Gjøen, T., & Seglen, P. O. (1997) · PubMed · Cited by 45
In vivo fate of folate–BSA in non‐tumor‐ and tumor‐bearing mice
Shinoda, T., Takagi, A., Maeda, A., Kagatani, S., Konno, Y., & Hashida, M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980215v · Cited by 39
Pharmaceutical nanotechnology: More than size
Florence, A. T. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.009 · Cited by 33
Kranenborg, M. H. G. C., Boerman, O. C., Oosterwijk‐Wakka, J. C., de Weijert, M. C. A., Corstens, F. H. M., & Oosterwijk, E. (1998) · International Journal of Cancer · Cited by 27
Soni, N., & Margarson, M. (2004) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2004.01.004 · Cited by 17
Cited by
Fang, J., Islam, W., & Maeda, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.005 · Cited by 757
Controlled drug delivery systems: Past forward and future back
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.054 · Cited by 720
Self-citationRecent applications of PLGA based nanostructures in drug delivery
Mir, M., Ahmed, N., & Rehman, A. U. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.07.038 · Cited by 621
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Facing the Truth about Nanotechnology in Drug Delivery
Park, K. (2013) · ACS Nano · doi:10.1021/nn404501g · Cited by 544
Self-citation
Metadata
- Authors
- Kwon, I. K., Lee, S. C., Han, B., & Park, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 164
- Issue
- 2
- Pages
- 108-114
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2066459637
- Cited by
- 404
- References
- 54
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.